Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

71.07USD
22 Jun 2018
Change (% chg)

$-0.45 (-0.63%)
Prev Close
$71.52
Open
$71.69
Day's High
$71.76
Day's Low
$70.83
Volume
2,411,073
Avg. Vol
2,416,486
52-wk High
$89.53
52-wk Low
$64.27

Latest Key Developments (Source: Significant Developments)

Gilead, Galapagos Announce Results With Filgotinib In Phase 2 EQUATOR Study In Psoriatic Arthritis
Thursday, 31 May 2018 

May 30 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS.GALAPAGOS NV - EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16.GALAPAGOS - CO TO GET $15 MILLION PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS.GALAPAGOS NV - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED.GALAPAGOS NV - THERE WAS ONE SERIOUS INFECTION IN FILGOTINIB GROUP, A PATIENT WHO EXPERIENCED PNEUMONIA WITH A FATAL OUTCOME IN TRIAL.GALAPAGOS NV - IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER.GALAPAGOS NV - THERE WERE NO CASES OF OPPORTUNISTIC INFECTION, TUBERCULOSIS, THROMBOEMBOLISM, OR MALIGNANCY IN TRIAL.  Full Article

FDA Approves Expanded Indication For Truvada
Tuesday, 15 May 2018 

May 15 (Reuters) - Gilead Sciences Inc ::U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADA® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS.GILEAD SCIENCES - U.S. FDA HAS APPROVED ONCE-DAILY ORAL TRUVADA TO REDUCE RISK OF SEXUALLY ACQUIRED HIV-1 IN AT-RISK ADOLESCENTS.  Full Article

Gilead's Kite Announces New Facilities, Expands Collaboration With National Cancer Institute
Tuesday, 15 May 2018 

May 15 (Reuters) - Gilead Sciences Inc ::KITE ANNOUNCES NEW WORLDWIDE FACILITIES AND EXPANDED COLLABORATION WITH NATIONAL CANCER INSTITUTE TO SUPPORT CELL THERAPY PIPELINE.KITE - ANNOUNCED IT HAS LEASED A NEW FACILITY IN NETHERLANDS TO ENGINEER CELL THERAPIES IN EUROPE.KITE - FACILITY TO ENGINEER, PRODUCE INNOVATIVE CELL THERAPIES, INCLUDING AXICABTAGENE CILOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY.  Full Article

Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018
Wednesday, 2 May 2018 

May 1 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018.  Full Article

Gilead Sciences Reports Q1 EPS $1.17
Wednesday, 2 May 2018 

May 1 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY DILUTED EPS OF $1.17 PER SHARE.QTRLY NON-GAAP DILUTED EPS OF $1.48 PER SHARE.REITERATES FULL YEAR 2018 GUIDANCE.QTRLY TOTAL REVENUES $5,088 MILLION VERSUS $6,505 MILLION REPORTED LAST YEAR.QTRLY HARVONI SALES $348 MILLION VERSUS $1,371 MILLION.Q1 EARNINGS PER SHARE VIEW $1.67, REVENUE VIEW $5.40 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $6.47, REVENUE VIEW $21.29 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Gilead And Verily Announce Scientific Collaboration
Tuesday, 1 May 2018 

April 30 (Reuters) - Gilead Sciences Inc ::GILEAD AND VERILY ANNOUNCE SCIENTIFIC COLLABORATION TO IDENTIFY AND UNDERSTAND IMMUNOLOGICAL AND MOLECULAR DRIVERS OF INFLAMMATORY DISEASES.GILEAD SCIENCES INC - VERILY TO DEPLOY ITS IMMUNOSCAPE PLATFORM TO GENERATE INSIGHTS FROM GILEAD CLINICAL TRIALS.GILEAD SCIENCES INC - THREE-YEAR COLLABORATION WITH VERILY LIFE SCIENCES.  Full Article

Kite Announces Clinical Collaboration With Pfizer
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Gilead Sciences Inc ::KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA.GILEAD SCIENCES INC - KITE ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH PFIZER, INC.GILEAD SCIENCES INC - MULTI-CENTER PHASE 1/2 STUDY SPONSORED BY KITE IS EXPECTED TO BEGIN IN 2018.GILEAD SCIENCES INC - RESULTS OF STUDY WILL BE USED TO EVALUATE OPTIONS FOR FURTHER DEVELOPMENT OF THE COMBINATION, OR SIMILAR COMBINATIONS.  Full Article

Teva Announces Exclusive Launch Of Generic Viread® In The United States
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED EXCLUSIVE LAUNCH OF GENERIC VIREAD TABLETS 300 MG IN U.S..  Full Article

Gilead Sciences and Kite To Acquire Cell Design Labs
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND KITE TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION.GILEAD SCIENCES INC - AGREEMENT INCLUDES AN INITIAL UPFRONT PAYMENT OF APPROXIMATELY $175 MILLION.GILEAD SCIENCES - DEAL INCLUDES ADDITIONAL PAYMENTS OF UP TO $322 MILLION PAID TO SHAREHOLDERS OF CELL DESIGN LABS OTHER THAN KITE UPON OCCURRENCE OF CERTAIN EVENTS.GILEAD SCIENCES - CO, CELL THERAPY UNIT KITE ANNOUNCED THEY ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH THEY AGREED TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES - WILL BUY ALL OF CELL DESIGN LABS' SHARES, WHICH INCLUDES ABOUT 12.2 PERCENT OF SHARES OF CELL DESIGN LABS CURRENTLY HELD BY KITE.  Full Article

X-Chem And Gilead Announce Drug Discovery Collaboration
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Gilead Sciences Inc ::X-CHEM AND GILEAD ANNOUNCE DRUG DISCOVERY COLLABORATION.‍X-CHEM-AS PER AGREEMENT, CO TO SCREEN PROPRIETARY DEX(TM) LIBRARIES TO DISCOVER THERAPEUTIC LEADS AGAINST TARGETS IN ANTIVIRAL, ADDITIONAL THERAPEUTIC AREAS​.X-CHEM- ‍UNDER TERMS ,CO TO RECEIVE UPFRONT PAYMENT, POTENTIAL LICENSING FEES,& ADDITIONAL PAYMENTS.X-CHEM​- GILEAD ‍HAS OPTION TO LICENSE DRUG LEADS DISCOVERED UNDER COLLABORATION, FOR FURTHER DEVELOPMENT, COMMERCIALIZATION OF RESULTING PROGRAMS.  Full Article

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.